Have HAART, will tackle HIVMarch 19th, 2009 - 6:04 pm ICT by IANS
Washington, March 19 (IANS) Highly active anti-retroviral therapy - or HAART - has emerged as a highly potent HIV treatment, a study has revealed.
However, HAART can never truly eradicate the viruses as some of them always remain dormant in cells.
But a chemical called suberoylanilide hydroxamic acid (SAHA), recently approved as leukemia drug, has now been shown to ‘turn on’ latent HIV, making it visible and easy to target that HAART misses.
Matija Peterlin at the University of California San Francisco (UCSF) and colleagues had previously identified another chemical called HMBA that could activate latent HIV, but the risk of several toxic side effects made HMBA clinically non-viable.
However, the chemically similar SAHA had received FDA approval, making it a potentially safer alternate.
So, the researchers examined whether SAHA had any effect on HIV latency. They found that SAHA could indeed stimulate latent HIV to begin replicating, which exposes the infected cell to HAART drugs, said a UCSF release.
SAHA could activate HIV in both lab cells as well as from blood samples taken from HIV patients on antiretroviral therapy. Importantly, this successful activation was achieved using clinical doses of SAHA, suggesting toxicity will not be a problem.
This study appeared in the March 13 issue of Journal of Biological Chemistry.
- How HIV reactivates after entering a dormant state - Feb 27, 2011
- Cancer drug successfully purges hidden HIV virus - Mar 09, 2012
- New HIV prevention strategy to benefit sufferers by cutting costs - Jul 08, 2010
- New approach for targeted killing of HIV virus - Aug 19, 2010
- Fresh hope for HIV patients - Mar 09, 2010
- How HIV escapes treatment - Mar 08, 2010
- Babies of HIV-positive women show exposure to antiretrovirals - Jul 22, 2012
- Russia tests HIV vaccine - Feb 06, 2012
- How 'silent HIV virus' attacks immune system - Sep 21, 2010
- Scientist unravels how HIV hijacks body defences - Jan 01, 2012
- HIV infection dropped 20 percent from 2001 to 2009: UN - Aug 26, 2011
- Study reinforces antiretroviral therapy's effectiveness in HIV prevention - Jul 20, 2010
- AIDS drugs block 99pc of HIV transmission to breastfed babies - Jun 17, 2010
- Aids cure to be found within 5 to 10 yrs - Jul 19, 2010
- New discovery may offer potential strategy for therapies to clear HIV - Jun 26, 2009
Tags: blood samples, california san francisco, fda approval, haart, hiv, hiv patients, hiv treatment, hmba, journal of biological chemistry, latency, latent hiv, leukemia, leukemia drug, march 19, peterlin, retroviral, toxic side effects, toxicity, ucsf, university of california san francisco